How to improve time-to-value using GxP computer systems
Explore the benefits of GxP computer systems to improve time-to-value so that companies can speed up the development and manufacture of life-saving drugs.
New process definition capabilities in PIMS enhance quality assurance and validation for pharma manufacturers
IDBS reveals new process definition-handling capabilities in PIMS 5.0, which enhance quality assurance and validation for pharma manufacturers.
IDBS appoints new General Manager
IDBS has appointed Pietro Forgione as its new General Manager.
How to speed up regulatory submission in drug development
Digital workflows with an “audit-by-exception” approach help reduce errors and time to compile data, and therefore delays to market.
IDBS and SciBite bring enterprise ontologies and scientific data management together through a new partnership to unlock value from data through improved interoperability
IDBS and SciBite announce a new partnership to shift the way research data platforms approach FAIR (Findable, Accessible, Interoperable, and Reusable) data.
New IDBS Polar data science capabilities democratize access to AI/ML-powered insights to accelerate BioPharma process optimization
IDBS announces the launch of new data science capabilities for its Polar platform to accelerate BioPharma process optimization.
Improve your data management for quicker time to regulatory submission
Data silos and inconsistent data formats increase the chance of errors, which can have a significant impact on business operations. Digital workflows are the answer.
How cloud technologies help advance BioPharma manufacturing
Explore how cloud-based solutions can improve data visibility and transparency so that partners can enjoy equal access to data at all stages of the BioPharma lifecycle.
Tech transfer needs a new blueprint. Here’s why.
Discover how a shared data backbone in tech transfer can remove inefficiencies and inconsistencies found in a one-time transfer approach.
Proper data management is crucial for speeding up the process of discovering and developing drugs
Do you have a vision for clean, contextualized data? Is IT accountable to the bench in your lab? Are you willing to value even the most unassuming insights?